Technologies
10 results found
Tag
Tag
Technologies
ID: 2019-015
Recombinant human Gal-1 treatment improves membrane repair capacity, increases myogenic markers and decreases inflammation in dysferlin deficient myotubes, providing novel evidence regarding how Gal-1 favorably improves muscle function in LGMD2B.